Seventure Partners

Aenitis Technologies is a French start-up founded in July 2014 by Mauricio Hoyos and Jean-Luc Aider, both researchers associated with the CNRS at the PMMH Laboratory in Paris. The company specializes in the development of medical devices aimed at enhancing cell therapy preparations. By utilizing acoustophoresis technologies, Aenitis Technologies creates innovative solutions for the separation, manipulation, and filtration of biological elements. Their focus is on addressing challenges faced by cell therapy units and blood banks, particularly in areas such as cell sorting, washing, and isolation. Aenitis Technologies aspires to lead the market in filtering and separating solutions through their advanced acoustic preparation techniques, with the ultimate goal of revolutionizing practices in public health.

Nexess SAS is a company that specializes in developing and selling security management solutions tailored for nuclear and Seveso-type plants. Founded in 2006 and based in Mougins, France, with an additional office in Paris, the company offers a range of products including NexLink, a software platform designed to enhance security and productivity. Its offerings also encompass various identification products such as personal security badges, RFID tags, and mobile devices, along with smart camera systems that provide autonomous image analysis and real-time data transmission. Nexess's solutions are utilized for applications like hazardous product traceability, managing smart secured cabinets, site localization, and monitoring access to hazardous zones. By integrating technologies such as RFID, Nexess supports major digital transformation projects, enhancing clients' performance in productivity, quality, and security.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

HARDLOOP SARL is an online retailer based in Paris, France, specializing in sports products and adventure gear. Founded in 2014, the company offers a wide range of items, including shoes, gloves, bottles, and various accessories tailored for outdoor activities such as hiking, trail running, skiing, climbing, and swimming. By providing a diverse selection from international brands, HARDLOOP aims to equip sports enthusiasts with the necessary gear for their adventures. The platform facilitates easy access to quality sports apparel and accessories, catering to the needs of active individuals seeking to enhance their outdoor experiences.

Expensya SAS, founded in 2014 and based in Paris, France, specializes in expense management software solutions. Its flagship product, the Expensya application, is a web and mobile platform that automates the management of professional expense reports from receipt processing to archiving. The software incorporates advanced technologies such as Cloud computing, Artificial Intelligence, and Big Data to enhance efficiency in expense management. It offers features including expense tracking, data export, accountant integration, approval workflows, and mileage management, while also supporting local accounting regulations in approximately fifty countries. The platform is available in eight languages, catering to the diverse needs of businesses and simplifying the claims process.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.

HARDLOOP SARL is an online retailer based in Paris, France, specializing in sports products and adventure gear. Founded in 2014, the company offers a wide range of items, including shoes, gloves, bottles, and various accessories tailored for outdoor activities such as hiking, trail running, skiing, climbing, and swimming. By providing a diverse selection from international brands, HARDLOOP aims to equip sports enthusiasts with the necessary gear for their adventures. The platform facilitates easy access to quality sports apparel and accessories, catering to the needs of active individuals seeking to enhance their outdoor experiences.

Expensya SAS, founded in 2014 and based in Paris, France, specializes in expense management software solutions. Its flagship product, the Expensya application, is a web and mobile platform that automates the management of professional expense reports from receipt processing to archiving. The software incorporates advanced technologies such as Cloud computing, Artificial Intelligence, and Big Data to enhance efficiency in expense management. It offers features including expense tracking, data export, accountant integration, approval workflows, and mileage management, while also supporting local accounting regulations in approximately fifty countries. The platform is available in eight languages, catering to the diverse needs of businesses and simplifying the claims process.

Launchmetrics is a marketing and analytics platform that specializes in serving the fashion, luxury, and beauty industries. Founded in 2006 and headquartered in New York, with additional operations in Paris, the company offers a suite of products designed to enhance brand performance and streamline marketing processes. Its offerings include Samples, Events, Contacts, Discover, and Influencers by Launchmetrics, which collectively assist brands in planning product launches and improving media performance. The company has established itself as a trusted technology provider, working with over 1,000 clients, including prominent names like Dior, Fendi, and NET-A-PORTER, as well as partners such as the British Fashion Council and Google. With a presence in eight markets and support in five languages, Launchmetrics aims to empower brands to create impactful and measurable consumer experiences, adapting to the rapidly changing digital landscape. The company was originally known as Fashion GPS, Inc. before rebranding in January 2016.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

Intento Design SA specializes in developing software solutions that enhance the design and migration processes of analog and mixed-signal integrated circuits. Founded in 2015 and headquartered in Paris, France, the company offers ID-Xplore, a tool that automates circuit sizing and streamlines the analog design process, significantly reducing latency. In addition to its software, Intento Design provides services such as methodology adoption, design collaboration, and technology migration. Their innovative approach aims to address productivity challenges faced by electrical designers, particularly in industries like consumer electronics, the Internet of Things, big data, military, and medical markets. The company's work is rooted in research conducted at the Laboratoire d’Informatique de Paris 6, leading to a robust portfolio of intellectual property that supports its mission to simplify and accelerate the analog design cycle for complex systems on chip (SoCs) used in various connected applications.

Botfuel, established in 2016 and headquartered in Paris, France, specializes in a web-based platform and SDK for creating and deploying chatbots. It empowers individuals and businesses to engage with customers on popular messaging channels, providing automated, personalized support and enhancing brand engagement. The company's AI-driven technology enables the development of modular, scalable chatbots, aiming to improve customer support and drive sales.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

MilliDrop Instruments SAS specializes in the design and development of cell culture machines utilizing millifluidics technology for bacteriological research and diagnostic applications. Founded in 2015 and based in Paris, France, the company offers advanced in vitro diagnostic machines that facilitate the incubation, analysis, and manipulation of samples, with volumes ranging from approximately 100 nanolitres to a few picolitres. Their innovative MilliDrop DIV instruments enable users to identify infectious agents and determine the appropriate antibiotic doses needed to effectively combat them, thereby minimizing therapeutic failures linked to improper antibiotic selection or excessive dosages. Additionally, MilliDrop's analyzers allow for the simultaneous study and cultivation of various cell cultures, as well as the sorting of phenotypes of interest and conducting serial dilutions, supporting microbiologists in their efforts to screen microbes for antimicrobial susceptibility testing.

Intento Design SA specializes in developing software solutions that enhance the design and migration processes of analog and mixed-signal integrated circuits. Founded in 2015 and headquartered in Paris, France, the company offers ID-Xplore, a tool that automates circuit sizing and streamlines the analog design process, significantly reducing latency. In addition to its software, Intento Design provides services such as methodology adoption, design collaboration, and technology migration. Their innovative approach aims to address productivity challenges faced by electrical designers, particularly in industries like consumer electronics, the Internet of Things, big data, military, and medical markets. The company's work is rooted in research conducted at the Laboratoire d’Informatique de Paris 6, leading to a robust portfolio of intellectual property that supports its mission to simplify and accelerate the analog design cycle for complex systems on chip (SoCs) used in various connected applications.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

Augure is a software company founded in 2002 in Paris, specializing in influencer marketing and public relations solutions. The company offers a platform that assists brands and agencies in managing their communication strategies by bridging the gap between traditional PR and influencer marketing. With over 1,000 clients utilizing the platform daily, Augure enables communication, PR, and public affairs teams to engage with relevant influencers, streamline campaign management, and enhance their media presence on social networks. In addition to its software, Augure provides consulting services through its data services team, helping clients interpret and leverage data to optimize their influencer marketing strategies. The company operates primarily in Europe and Latin America, serving a diverse range of clients, including prominent organizations in the corporate sector.

Aenitis Technologies is a French start-up founded in July 2014 by Mauricio Hoyos and Jean-Luc Aider, both researchers associated with the CNRS at the PMMH Laboratory in Paris. The company specializes in the development of medical devices aimed at enhancing cell therapy preparations. By utilizing acoustophoresis technologies, Aenitis Technologies creates innovative solutions for the separation, manipulation, and filtration of biological elements. Their focus is on addressing challenges faced by cell therapy units and blood banks, particularly in areas such as cell sorting, washing, and isolation. Aenitis Technologies aspires to lead the market in filtering and separating solutions through their advanced acoustic preparation techniques, with the ultimate goal of revolutionizing practices in public health.

Open Ocean SAS is a company that specializes in developing a SaaS-based decision-making platform focused on managing offshore infrastructure and marine operations. Founded in 2011 and headquartered in Paris and Brest, the company offers a range of products and services, including the Metocean Analytics solution, which analyzes atmospheric and oceanic conditions, and a detailed report on the tidal energy market in France. Additionally, Open Ocean provides a spectral wave database for Scotland, facilitating the development of marine renewable energy. Its services encompass site data analysis, resource and energy assessment, environmental data for design calculations, and research and development for offshore energy projects. Open Ocean caters to farm developers, operators, and public agencies within the renewable marine energy sector, leveraging a highly qualified team of oceanographers skilled in high-resolution modeling and data analysis.

JobTeaser SARL operates a recruitment platform designed specifically for students and recent graduates. Founded in 2008 and based in Paris, France, the company facilitates the search for internships and entry-level jobs through its online platform, which offers tailored opportunities based on user profiles. JobTeaser is integrated into over 750 educational institutions, providing access to 5 million users and enabling more than 250,000 recruiters to connect with emerging talent. The platform not only assists with job placements but also offers career guidance, videos to explore various career paths, and advice on making informed career choices. Additionally, it includes features that allow direct communication between job seekers and recruiters, enhancing the overall job search experience.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Nexess SAS is a company that specializes in developing and selling security management solutions tailored for nuclear and Seveso-type plants. Founded in 2006 and based in Mougins, France, with an additional office in Paris, the company offers a range of products including NexLink, a software platform designed to enhance security and productivity. Its offerings also encompass various identification products such as personal security badges, RFID tags, and mobile devices, along with smart camera systems that provide autonomous image analysis and real-time data transmission. Nexess's solutions are utilized for applications like hazardous product traceability, managing smart secured cabinets, site localization, and monitoring access to hazardous zones. By integrating technologies such as RFID, Nexess supports major digital transformation projects, enhancing clients' performance in productivity, quality, and security.

Biophytis SA is a clinical-stage biotechnology company based in Paris, France, dedicated to developing therapeutics that aim to slow degenerative processes linked to aging and enhance functional outcomes for patients with age-related diseases. The company focuses on activating key biological resilience pathways to mitigate the effects of various biological and environmental stresses that contribute to these conditions. Biophytis has two primary drug candidates: Sarconeos (BIO101), an orally administered small molecule being developed for neuromuscular diseases such as sarcopenia and Duchenne muscular dystrophy, and Macuneos (BIO201), also an orally administered small molecule targeting retinal diseases like dry age-related macular degeneration and Stargardt disease. The company has established a collaboration agreement with AFM-Telethon for the development of Sarconeos. Founded in 2006, Biophytis aims to become a leader in aging science by providing innovative therapies to address the needs of patients with limited treatment options.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Impeto Medical SAS is a privately owned medical device company based in Paris, France, established in 2005. The company specializes in manufacturing and marketing non-invasive devices that assess eccrine sweat gland activity. Its key products include SUDOSCAN+, which detects and monitors peripheral autonomic neuropathy; EZSCAN, designed for screening and preventing diabetes and cardiometabolic risks; and SUDOSCAN, which evaluates galvanic skin response to assess the sympathetic nervous system's behavior in various conditions, including diabetes and Parkinson's disease. Impeto Medical utilizes patented technology to analyze sudomotor function, enabling healthcare providers to screen large patient populations for early detection of diseases and complications. The company distributes its products through a network of distributors and has subsidiary locations in China and San Diego, California.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Arlettie, originally founded as Espace Max in 1993, is based in Paris, France, and specializes in online retail of luxury fashion apparel and accessories. The company operates as an event organizer for private sales and exclusive shopping events, acting as an intermediary between luxury brands and customers. Through its platform, Arlettie offers a curated selection of high-end fashion, accessories, and lifestyle products from renowned brands, facilitating unique shopping experiences for consumers seeking exclusive items.

EffiCity SAS is an online real estate agency based in Paris, France, established in 2007. The company specializes in providing a range of real estate services, including the buying and selling of properties, as well as property management and valuation. EffiCity utilizes digital platforms to facilitate transactions, making it easier for clients to navigate the real estate market.

Glowria offers online digital video disc (DVD) rental service. Glowria was founded in 2003 is based in Paris, France.

Sefas Innovation, founded in 1991 and headquartered in Paris, France, specializes in collaborative document composition and production software. With offices in the UK and the US, the company employs over 80 staff and has been serving Fortune 500 clients for more than 15 years. Its flagship product, the Open Print software suite, is designed for sectors such as financial services, banking, insurance, utilities, telecommunications, and the public sector. Open Print enables the design, composition, and production of complex, data-driven B2C documents, allowing organizations to integrate multiple data sources for personalized communications. The software is increasingly utilized to revamp mission-critical documents to align with the latest marketing initiatives, thereby enhancing revenue opportunities. Notable clients in the UK include Nationwide, HBOS, and British Telecom, all of whom have utilized Open Print since the early 2000s.

DSO Interactive SA designs, develops, and markets software solutions for intermediation of Internet platforms. Its products include auditing and decisional software systems for legal firms. The company also offers information technology and communication consulting services. It was formerly known as Convergence SA and changed its name to DSO Interactive in September 2004. The company was founded in 2001 and is based in Paris, France.